DBV snags 1st food allergy drug 'breakthrough' status
This article was originally published in Scrip
Executive Summary
French drug maker DBV Technologies has been granted breakthrough therapy designation by the FDA for Viaskin Peanut, an investigational treatment for peanut allergy in children.